Lilly Announces Upcoming Presentation of New Data Indicating Rise in Opioid Use for Migraine Treatment

Lilly Announces Upcoming Presentation of New Data Indicating Rise in Opioid Use for Migraine Treatment

Publication date: Jul 11, 2019

-Findings showed that nearly 1 in 5 people with migraine (19%) are currently using opioids to treat their disease, up from 16 percent in 2009(1,2) -OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) aims to further understand the burden, stigma and barriers experienced by people living with migraine INDIANAPOLIS, July 10, 2019 /PRNewswire/ — Eli Lilly and Company (LLY) today announced the upcoming presentation of data indicating rising rates of opioid use for the treatment of migraine based on results from the OVERCOME ( bser ational Survey of the pidemiology, T eatment and are of igrain ) study. 1 These findings will be presented on Saturday, July 13, 2019, at the 61st Annual Scientific Meeting of the American Headache Society taking place in Philadelphia.

Despite opioids typically being reserved for limited or highly specific uses and not a treatment of choice for migraine, results from OVERCOME demonstrated that a high number of people are using opioids to treat their migraine. 1,3 These findings suggest that the real-world treatment of migraine is falling short of current scientific understanding of how to optimally treat this serious and disabling neurologic disease.

“The data from OVERCOME showed that, overall, opioids are being used in place of medicines that are approved and indicated to treat migraine, particularly among those who experience migraine headaches more frequently,” said Sait Ashina, M. D., Department of Neurology and Department of Anesthesia, Critical Care and Pain Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA.

The seminal 2009 American Migraine Prevalence and Prevention Study demonstrated that 16 percent of people with migraine were currently using opioids at the time of the study. 2 Data from OVERCOME collected in 2018 showed 19 percent of people with migraine were currently using opioids specifically to treat migraine. 1 This could represent a potential increase of tens of thousands of adults using opioids for migraine compared to the previous decade. 1,2 Furthermore, among OVERCOME participants who reported four or more migraine headaches per month, nearly 1 in 4 were currently using opioids (23. 9%) and more than 50 percent of people in this group reported using opioids at some point to treat their migraine. 1 “While diagnosis and treatment in migraine has significantly improved during the past decade or so, it’s clear that for many, sub-optimal care is still a reality,” said Eric Pearlman, M. D., Ph. D, senior medical director, U. S. neuroscience, Eli Lilly and Company.

About the OVERCOME Study The bser ational Survey of the pidemiology, T eatment and are f igrain (OVERCOME) study aims to further understand the burden of migraine and stigma experienced by people living with the disease, identify barriers to appropriate treatment of migraine and assess how the introduction of novel treatment options may influence delivery of migraine care and outcomes.

About the OVERCOME Scientific Advisory Board The OVERCOME study is being conducted by Kantar on behalf of Eli Lilly and Company with expert guidance provided by some of the leading voices in migraine research today, including: , Ph. D., Department of Neurology, of Medicine, Clinical Health Psychology Doctoral Program of the Ferkauf , M. D., Department of Neurology and Department of Anesthesia, Critical Care and Pain Medicine, and , Beth Israel Deaconess Medical Center About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world.

Concepts Keywords
Anesthesia Neuroscience
Ashina Prevention of migraines
Boston Headache
Clinical Psychology Opioid
Comand Migraine treatment
Eli Lilly Clinical medicine
Global Healthcare Organ systems
Globe Migraine
Harvard Voices migraine
Headache Unique perspective migraine
Healthcare Delivery migraine
Holistic Percent migraine
Israel Barriers treatment migraine
MA Migraine headaches
Migraine Burden migraine
Neurologic Disease Diagnosis treatment migraine
Neurological Management disease
Neurology Prospective web
Neuroscience Efforts organizations
Opioid Migraine Treatment
Opioid Epidemic Percent
Opioids Migraine care
Philadelphia
Philanthropy
Stigma
Survey
Volunteerism

Semantics

Type Source Name
drug DRUGBANK Nonoxynol-9
disease DOID Migraine
disease MESH Migraine
gene UNIPROT AHSG
disease MESH communities
gene UNIPROT FBXW7
disease MESH diagnosis
gene UNIPROT EHD1
drug DRUGBANK Etodolac
gene UNIPROT RGS6
gene UNIPROT RASA1
drug DRUGBANK Tropicamide

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *